comprehensive -WSS

comprehensive

author：explore 2025-09-30 12:10:34 - browse：98

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Caribou posts encouraging results on off

hotspot

WSS

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

In rare move, senator releases unverified FBI source report alleging Biden bribe

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

A new ‘biological computer' targets cancer while sparing healthy cells

Leukemia patients are helped by Syndax's new type of therapy

Wikipedia

comprehensive

focus

In age of alternative facts, a scholarly course on calling out crap

How a Boston hospital is priming medical residents to use GPT

Bright Health sells Medicare Advantage business to Molina

'CMA Fest' 2023: How to watch, who is performing and more

DIEP, the 'gold standard' of breast reconstruction, is under threat

The stock market has soared this year, but will it last? Experts weigh in

Medical records are filled with copy

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

How one medical school became remarkably diverse

What PEPFAR has meant on the ground in Ukraine

Wikipedia

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

CMS should re

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

SCOTUS to consider access to abortion pill mifepristone

Patients' immediate access to test results puts radiologists in a bind

knowledge

Wikipedia

hotspot

hotspot